for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Thermo Fisher Scientific Inc.

TMO

Latest Trade

417.73USD

Change

3.78(+0.91%)

Volume

599,148

Today's Range

417.73

 - 

423.70

52 Week Range

250.21

 - 

423.70

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
413.95
Open
418.25
Volume
599,148
3M AVG Volume
29.21
Today's High
423.70
Today's Low
417.73
52 Week High
423.70
52 Week Low
250.21
Shares Out (MIL)
395.59
Market Cap (MIL)
163,490.00
Forward P/E
27.52
Dividend (Yield %)
0.21

Next Event

Dividend For TMO.N - 0.2200 USD

Latest Developments

More

Thermo Fisher Scientific Says Co And Lyell Immunopharma Form Cell Therapy Manufacturing Partnership

Thermo Fisher Scientific Reports Q2 Adj EPS $3.89

Qiagen Publishes Position Statement For Proposed Acquisition By Thermo Fisher

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.

Industry

Medical Equipment & Supplies

Contact Info

168 3rd Ave

WALTHAM, MA

02451-7551

United States

+1.781.6221000

https://www.thermofisher.com/

Executive Leadership

Marc N. Casper

Chairman of the Board, President, Chief Executive Officer

Stephen Williamson

Chief Financial Officer, Senior Vice President

Mark P. Stevenson

Chief Operating Officer, Executive Vice President

Michel Lagarde

Executive Vice President

Michael A. Boxer

Senior Vice President, General Counsel

Key Stats

1.67 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

20.9K

2018

24.4K

2019

25.5K

2020(E)

28.1K
EPS (USD)

2017

9.490

2018

11.120

2019

12.350

2020(E)

15.043
Price To Earnings (TTM)
44.46
Price To Sales (TTM)
6.23
Price To Book (MRQ)
5.48
Price To Cash Flow (TTM)
27.10
Total Debt To Equity (MRQ)
71.34
LT Debt To Equity (MRQ)
69.08
Return on Investment (TTM)
7.04
Return on Equity (TTM)
6.25

Latest News

Latest News

Davidson Kempner ups stake in Qiagen to 7.3%

Hedge fund Davidson Kempner has raised its stake in takeover target Qiagen <QIA.DE> to 7.3% from 5.1% previously, having rejected a sweetened offer for the German group from U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.

Qiagen investor PSquared won't tender shares in Thermo Fisher bid

Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen <QIA.DE>, adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.

Thermo Fisher's sweetened Qiagen bid fails to win over key investor

Thermo Fisher Scientific <TMO.N> raised its bid for Qiagen <QIA.DE> by 900 million euros ($1 billion) on Thursday but failed to win over a key investor who is seeking a higher price for the German genetic test maker.

Davidson Kempner spurns Thermo Fisher's Qiagen offer as 'wholly inadequate'

Hedge fund Davidson Kempner said on Wednesday Thermo Fisher Scientific's <TMO.N> offer to buy German genetic test maker Qiagen <QIA.DE> was "wholly inadequate" and that it would not be tendering its shares into the deal at the current price.

Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'

Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's <TMO.N> current offer to acquire German genetic test maker Qiagen NV <QIA.DE> to be "inadequate" and would not tender its shares into the offer.

Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'

Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's current offer to acquire German genetic test maker Qiagen NV to be "inadequate" and will not tender its shares into the offer.

BRIEF-Thermo Fisher Scientific Sets Quarterly Cash Dividend Of $0.22 Per Share

* SETS QUARTERLY CASH DIVIDEND OF $0.22PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Thermo Fisher Scientific Signs Companion Diagnostic Agreement With Chugai Pharmaceutical

* THERMO FISHER SCIENTIFIC SIGNS COMPANION DIAGNOSTIC AGREEMENT WITH CHUGAI PHARMACEUTICAL

BRIEF-Thermo Fisher Scientific - Estimates Both Reported, Organic Revenue Growth Will Be About 10% For Q2

* THERMO FISHER SCIENTIFIC - ESTIMATES BOTH REPORTED, ORGANIC REVENUE GROWTH WILL BE ABOUT 10% FOR Q2

Major Qiagen shareholder demands higher bid from Thermo Fisher - source

The coronavirus pandemic has boosted Qiagen's <QIA.DE> prospects and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.

Major Qiagen shareholder opposes Thermo Fisher takeover - source

The coronavirus pandemic has boosted Qiagen's prospects as a standalone company and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.

BRIEF-Thermo Fisher Scientific Launches New MAS Omni Infectious Disease Quality Controls

* THERMO FISHER SCIENTIFIC LAUNCHES NEW MAS OMNI INFECTIOUS DISEASE QUALITY CONTROLS Source text for Eikon: Further company coverage:

BRIEF-Schrödinger Collaborates With Thermo Fisher To Expand Structure-Based Drug Discovery

* SCHRÖDINGER ANNOUNCES STRATEGIC COLLABORATION WITH THERMO FISHER SCIENTIFIC TO EXPAND STRUCTURE-BASED DRUG DISCOVERY TO NOVEL TARGETS USING CRYO-EM

BRIEF-Thermo Fisher, Daiichi Sankyo To Co-Develop Global Companion Diagnostic For Non-Small Cell Lung Cancer

* THERMO FISHER SCIENTIFIC AND DAIICHI SANKYO TO CO-DEVELOP GLOBAL COMPANION DIAGNOSTIC FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER

BRIEF-FDA Grants Breakthrough Device Designation To Thermo Fisher's Oncomine Precision Assay

* U.S. FDA - HAS GRANTED BREAKTHROUGH DEVICE DESIGNATION TO THERMO FISHER SCIENTIFIC'S ONCOMINE PRECISION ASSAY Source text for Eikon: Further company coverage:

BRIEF-Thermo Fisher Entered Term Loan Credit Agreement

* THERMO FISHER - ON JUNE 5, ENTERED TERM LOAN CREDIT AGREEMENT REPLACING EUR3.0 BILLION BRIDGE LOAN FACILITY WITH EUR3.0 BILLION SENIOR UNSECURED 1-YEAR TERM FACILITY

BRIEF-Genetron Holdings Says Entered Strategic Partnership Agreement With Thermo Fisher

* GENETRON HOLDINGS LIMITED SAYS ENTERED STRATEGIC PARTNERSHIP AGREEMENT WITH THERMO FISHER SCIENTIFIC WITH PLANS TO BUILD ON SEQUENCER GENETRON S5 Source text for Eikon: Further company coverage:

BRIEF-PharmAbcine Execute An Agreement With Thermo Fisher For Development, Manufacturing Of Its Next-Generation Immune Checkpoint Blockade

* PHARMABCINE EXECUTE AN AGREEMENT WITH THERMO FISHER FOR THE DEVELOPMENT AND MANUFACTURING OF ITS NEXT-GENERATION IMMUNE CHECKPOINT BLOCKADE, PMC-309 FOR PHASE I Source text for Eikon: Further company coverage:

BRIEF-Thermo Fisher To Co-Develop A Global Companion Diagnostic For Low-Grade Glioma With Agios Pharmaceuticals

* THERMO FISHER SCIENTIFIC - TO CO-DEVELOP A GLOBAL COMPANION DIAGNOSTIC FOR LOW-GRADE GLIOMA WITH AGIOS PHARMACEUTICALS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up